Although the company will continue to pursue « higher-risk, high reward » drug candidates such as pegilodecakin, these will be a smaller part of the portfolio in the future, said Chief Scientific Officer Daniel Skovronsky. Nicholas Hewlett, head of St Dunstan’s College private school in southeast London, said staff were worried by a ‘righteous generation’ of children […]